SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 194 filers reported holding SAGE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $479,780 | +1329.1% | 23,313 | +3165.1% | 0.00% | – |
| Q2 2023 | $33,572 | +15.3% | 714 | +2.9% | 0.00% | – |
| Q1 2023 | $29,120 | +25.0% | 694 | +13.6% | 0.00% | – |
| Q4 2022 | $23,303 | +1.3% | 611 | 0.0% | 0.00% | – |
| Q3 2022 | $23,000 | +21.1% | 611 | 0.0% | 0.00% | – |
| Q2 2022 | $19,000 | -98.2% | 611 | -98.1% | 0.00% | -100.0% |
| Q1 2022 | $1,048,000 | -71.2% | 31,715 | -62.7% | 0.00% | -66.7% |
| Q4 2021 | $3,634,000 | -6.5% | 85,104 | -3.1% | 0.01% | -14.3% |
| Q3 2021 | $3,885,000 | +65.2% | 87,797 | +111.4% | 0.01% | +75.0% |
| Q2 2021 | $2,352,000 | -29.0% | 41,538 | -6.5% | 0.00% | -33.3% |
| Q1 2021 | $3,312,000 | -63.6% | 44,405 | -57.6% | 0.01% | -66.7% |
| Q4 2020 | $9,087,000 | +42.1% | 104,848 | +0.0% | 0.02% | +28.6% |
| Q3 2020 | $6,394,000 | +62.1% | 104,814 | +10.4% | 0.01% | +55.6% |
| Q2 2020 | $3,945,000 | +273.9% | 94,919 | +159.0% | 0.01% | +200.0% |
| Q1 2020 | $1,055,000 | +339.6% | 36,651 | +998.3% | 0.00% | – |
| Q4 2019 | $240,000 | -65.2% | 3,337 | -32.1% | 0.00% | -100.0% |
| Q3 2019 | $690,000 | +72.1% | 4,917 | +124.4% | 0.00% | 0.0% |
| Q2 2019 | $401,000 | +9.9% | 2,191 | -4.6% | 0.00% | 0.0% |
| Q1 2019 | $365,000 | -98.0% | 2,297 | -98.8% | 0.00% | -97.6% |
| Q4 2018 | $18,254,000 | -33.1% | 192,364 | -0.7% | 0.04% | -21.2% |
| Q3 2018 | $27,286,000 | +42.6% | 193,730 | +57.8% | 0.05% | +30.0% |
| Q2 2018 | $19,129,000 | +26.2% | 122,768 | +30.5% | 0.04% | +53.8% |
| Q1 2018 | $15,156,000 | -13.1% | 94,091 | -10.4% | 0.03% | -10.3% |
| Q4 2017 | $17,450,000 | +760.9% | 105,003 | +222.8% | 0.03% | +866.7% |
| Q3 2017 | $2,027,000 | +7.3% | 32,530 | +37.1% | 0.00% | 0.0% |
| Q2 2017 | $1,889,000 | +35.0% | 23,722 | +20.5% | 0.00% | 0.0% |
| Q1 2017 | $1,399,000 | +160.0% | 19,679 | +82.1% | 0.00% | +200.0% |
| Q4 2016 | $538,000 | – | 10,807 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |